Eurolab has appointed Tribeca Public Relations (Tribeca) as its public relations partner, tasking the award-winning agency to position the company as market leaders in oncology through its unique whole-of-cancer approach.
Eurolab is the largest generic oncology company in South Africa, with a strategic growth plan that deliver innovations in all aspects of cancer diagnosis, treatments, therapies and technologies. Its whole-of-cancer approach focuses on patients, their health, and relieving their financial stress during – and after – their life-threatening illness.
“Our business has experienced rapid growth, and because we have a multitude of new cancer treatments, therapies and technologies on the horizon, we’re poised to expand even further” says Lynne du Toit, CEO of Eurolab. “We realised the need for an effective communications partner to tell our story, and chose Tribeca as we believe that the team will get us talking to the people important to our business: oncologists, radiation oncologists, and most importantly, the patients who can benefit from our innovative range of cancer products, services and solutions.”
“Tribeca applies solid public relations principles to each client we work with to help them achieve their goals, regardless of their industry,” says Cian Mac Eochaidh, co-owner and director of Tribeca Public Relations. “We particularly enjoy working with South African companies that are making a positive difference to the country’s citizens, and we look forward to helping Eurolab achieve its communication and business objectives.”
“Our business has experienced rapid growth, and because we have a multitude of new cancer treatments, therapies and technologies on the horizon, we’re poised to expand even further” says Lynne du Toit, CEO of Eurolab. “We realised the need for an effective communications partner to tell our story, and chose Tribeca as we believe that the team will get us talking to the people important to our business: oncologists, radiation oncologists, and most importantly, the patients who can benefit from our innovative range of cancer products, services and solutions.”
